Dr. Hatem Ghazal, a specialist in embryology, revealed friday, October 1, 2021, that Merck Laboratories has just announced a success for its clinical trials launched last April on an anti-CORONA virus drug.
“The drug has been tested on 775 people with coruna who are at risk of serious conditions (obesity, diabetes, heart disease) and trials have shown that taking it protects against serious conditions by 50% compared to those who do not have the drug and no deaths compared to 8 deaths in the group that did not receive it,” he said in a blog post on his Facebook page.
“This is a new scientific opening that will save hundreds of thousands of lives if it receives fda approval,” he said, adding that the US government has announced its desire to acquire 1.7 million doses.
The U.S. pharmaceutical company announced today that its covid-19 experimental pills have halved the hospitalization and mortality rate of people newly infected with CORONAvirus and will soon ask U.S. and around the world health officials to authorize their use.
If approved, Merck would be the first pill to appear to treat Covid-19, a potentially significant advance in efforts to combat the pandemic. All covid-19 treatments now authorized in the United States require intravenous or injectable receipt.
In March, the pharmaceutical company Merck announced progress in the development of a drug still under trial, but it showed positive effects on reducing the risk of the virus to patients, months after it halted the development of two potential COVID 19 vaccines.
The drug is called Molnoperavir, developed by Merck in partnership with U.S. Ridgeback Bayou.
Merck is also working on another treatment called MK 711, and the group said at the end of January that the first results of clinical trials show a more than 50 percent reduction in the risk of death or respiratory failure in hospital patients with moderate to severe forms of COVID 19.
Rifi-JDD
